10-Q: Papa Medical Reports Q3 2025 Loss Amid Revenue Decline

Papa Medical Inc. reported a significant net loss of $0.8 million for the three months ended September 30, 2025, driven by a 26.1% revenue decrease and increased operating expenses.

Summary

• Reported a net loss of $819,923 for the three months ended September 30, 2025, a significant decline from a net income of $304,471 in the same period of 2024.
• Total revenues decreased by 26.1% to $7.4 million for Q3 2025, down from $10.0 million in Q3 2024, primarily due to new regulations on product packaging.
• Gross profit plummeted by 41.8% to $1.4 million in Q3 2025, with the gross profit margin decreasing to 19.3% from 24.5% in Q3 2024.
• Operating expenses increased by 35.2% to $2.7 million for Q3 2025, compared to $2.0 million in Q3 2024.
• For the nine months ended September 30, 2025, total revenues increased by 46.4% to $39.9 million, up from $27.3 million in the prior year period, driven by expansion in the Hemp cannabinoid E-vapors customer base.
• Net income for the nine months ended September 30, 2025, decreased by 43.7% to $590,354, from $1,048,355 in the prior year period.
• Cash and cash equivalents significantly decreased to $857,529 as of September 30, 2025, from $4,749,842 as of December 31, 2024.
• Net cash used in operating activities was $3,337,162 for the nine months ended September 30, 2025, a substantial increase from $686,321 used in the prior year period.

Sentiment

Score: 3

Explanation: The significant net loss and revenue decline in Q3 2025, coupled with a substantial decrease in cash and increased cash burn from operations, indicate deteriorating short-term performance and potential liquidity concerns. While nine-month revenues grew, the accompanying decrease in net income and gross profit margin suggests underlying operational inefficiencies. The reliance on future IPO proceeds and potential equity financing for growth, against a backdrop of increasing operating expenses and regulatory risks, presents a high-risk investment profile with negative short-term momentum.

Positives

• Total revenues for the nine months ended September 30, 2025, increased by 46.4% to $39.9 million, primarily due to the expansion of the Hemp cannabinoid E-vapors customer base in the United States.
• Gross profit for the nine months ended September 30, 2025, increased by 33.8% to $9.1 million, attributed to increased sales volume and improved brand recognition.
• Interest income, net, increased for both the three months ($54 vs. -$14,036) and nine months ($118,389 vs. $30,346) ended September 30, 2025, compared to 2024.
• An income tax credit of $463,970 was recorded for the three months ended September 30, 2025, due to a decrease in taxable income generated from operations.

Negatives

• Net income decreased significantly to a loss of $819,923 for the three months ended September 30, 2025, from a profit of $304,471 for the same period in 2024.
• Total revenues for the three months ended September 30, 2025, decreased by 26.1% to $7.4 million, primarily due to new regulations on product packaging leading to slower order placements.
• Gross profit for the three months ended September 30, 2025, plummeted by 41.8% to $1.4 million, and the gross profit margin decreased to 19.3% from 24.5%.
• Operating income for the three months ended September 30, 2025, decreased by 390.9% to a loss of $1.3 million.
• Net income for the nine months ended September 30, 2025, decreased by 43.7% to $0.6 million, despite increased revenues, indicating significant cost pressures.
• Operating income for the nine months ended September 30, 2025, decreased by 58.5% to $0.6 million.
• Cash and cash equivalents decreased substantially from $4,749,842 at December 31, 2024, to $857,529 at September 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $3,337,162, a significant increase from $686,321 in the prior year period.
• Selling and marketing expenses increased by 35.2% for Q3 2025 and 60.6% for the nine months ended September 30, 2025.
• General and administrative expenses increased by 64.3% for Q3 2025 and 48.8% for the nine months ended September 30, 2025.
• Research and development expenses increased by 68.3% for Q3 2025 and 86.9% for the nine months ended September 30, 2025.
• Provision for stock obsolescence of inventories increased to $525,460 for the nine months ended September 30, 2025, from $123,342 in the prior year.
• Recorded a loss on disposal of property, plant and equipment of $54,653 for the nine months ended September 30, 2025.

Risks

• The business is significantly affected by legislation and regulations impacting the Hemp and consuming E-vapors industry.
• The development of an international market for E-vapors is currently primarily limited to certain states in the United States, restricting growth opportunities.
• Ability to obtain regulatory approval to market additional Hemp and consuming E-vapors in the United States, Europe, and other target countries and regions is crucial and uncertain.
• The company's ability to develop and market Hemp and consuming E-vapors that meet the changing tastes of users is a continuous challenge.
• Concentration of credit risk exists with cash and cash equivalents held in major financial institutions, with uninsured portions in U.S. banks totaling $212,657 as of September 30, 2025.
• High customer concentration, with two customers individually exceeding 10% of total revenues for both the three and nine months ended September 30, 2025.
• High supplier concentration, with three suppliers individually representing greater than 10% of total purchases for the nine months ended September 30, 2025.
• Potential for additional impairment losses on long-lived assets if significant adverse changes occur, such as intensified market competition or technology obsolescence.
• Legal proceedings and regulatory actions in the ordinary course of business carry inherent uncertainties and could have a material adverse effect on the business.

Future Outlook

Management expects selling and marketing expenses to continue increasing as the company expands its sales force and presence. Additional expenses are anticipated post-IPO due to public company operating costs. Research and development expenses are projected to vary as a percentage of revenue. The company expects to recognize $3.6 million in contract liabilities as revenue within the next three months. Management believes existing cash, operational cash flows, and capital market access will cover working capital for at least the next twelve months, not anticipating additional financing for liquidity needs within this period. However, business expansion plans may necessitate additional equity financing to scale production and meet market demand, and the company may seek equity or debt if cash requirements exceed current holdings. Future capital expenditures are planned to be funded by existing cash, bank loans, and IPO proceeds.

Management Comments

• "Our gross profit plummeted by 41.8% to US$1.4 million, compared to US$2.4 million for the three months ended September 30, 2024, primarily due to reduced sales."
• "Our gross profit margin decreased to 19.3% for the three months ended September 30, 2025, from 24.5% for the same period in 2024, primarily due to adjustments in product mix to meet evolving customer preferences."
• "For the nine months ended September 30, 2025, our gross profit by 33.8% to US$9.1 million, compared to US$6.8 million for the nine months ended September 30, 2024, primarily driven by expanded sales volumes."
• "The decrease in gross profit margin resulted from (i) volume-related cost increases that were not fully offset by economies of scale, and (ii) adjustments in product mix to meet evolving customer preferences."
• "Our total revenues decreased by approximately 26.1%... primarily due to the primarily by new regulations on product packaging, resulting in a slower pace of order placements from customers."
• "Our total cost of sales decreased by approximately 21.1%... primarily due to our increased cost of raw materials and increased manufacturing cost in line with the decreased sales..."
• "Our general and administrative expenses increased... primarily due to the increased labor cost and legal and professional fee."
• "Our research and development expenses increased... primarily due to the increased R&D personnel for our new series of E-vapors, iPrefer in the first quarter of 2025."
• "Our total revenues increased by approximately 46.4%... primarily due to the expansion of our Hemp cannabinoid E-vapors customer base in the United States, which is mainly driven by the increased demand on Hemp cannabinoid E-vapors by the customers."
• "Our gross profit margin increased from approximately 24.8%... to approximately 22.7%... primarily due to the increased cost of our products and the offering price discounts by the Company to new clients in order to stimulate sales and gain more market share, and due to adjustments in product mix to meet evolving customer preferences."
• "We believe that our existing cash balances, cash flows expected to be generated from operations, and access to capital markets will be sufficient to meet our working capital requirements for at least the next twelve months."
• "We do not anticipate requiring additional financing to meet our liquidity needs within the next twelve months."

Industry Context

Papa Medical Inc. operates in the Hemp cannabinoid E-vapors and consuming E-vapors industry, which is characterized by evolving legislation and regulations, as evidenced by new product packaging regulations impacting Q3 2025 revenues. The market for E-vapors is noted to be primarily limited to certain states in the United States, suggesting a fragmented or geographically constrained market. The company's growth is tied to its ability to navigate regulatory approvals for new products and adapt to changing consumer preferences. Despite Q3 challenges, the nine-month revenue growth in Hemp cannabinoid E-vapors indicates a segment with increasing demand, contrasting with broader regulatory headwinds.

Corporate Governance

Legal Proceedings

• The Group is not a party to any material legal or administrative proceedings as of September 30, 2025.
• The Group is subject to legal proceedings and regulatory actions in the ordinary course of business, the results of which cannot be predicted with certainty and could have a material adverse effect.

Related Party Transactions

• PAPA Health entered into a four-year business process outsourcing service agreement with Shenzhen Feellife (an affiliate controlled by the Principal shareholder) on January 1, 2022, with service expenses based on actual labor costs.
• Amounts due to Shenzhen Feellife included payables for the purchase of consumable Hemp cannabinoid E-vapors, packaging materials, and mould equipment.
• The Group transferred net amounts due from twelve related parties (FGP, Cpresso, Vplus, Shenzhen LFS, Feel Life, Hooloo, FL MEDICAL, FL GLOBE, Joincare, IOTA, FEELLIFE HOLDING, and Shenzhen Huacheng) totaling US$908,723 for the nine months ended September 30, 2025, and US$374,951 for the year ended December 31, 2024, to Shenzhen Feellife based on a Debit Waiver Agreement dated April 1, 2024.
• Amounts due from Cpresso, LLC (controlled by Shenzhen LFS) included a rental deposit of $11,000.
• Amounts due to Ms. Hua Yao (Chief Financial Officer) of US$105 as of September 30, 2025, representing reimbursements for office expenses.
• Revenue generated from Shenzhen Feellife was $11,428 for Q3 2025 and $15,677 for 9M 2025.
• Purchases from Shenzhen Feellife were $947,818 for Q3 2025 and $2,271,778 for 9M 2025.
• Service expenses paid to Shenzhen Feellife were $522,491 for Q3 2025 and $1,891,259 for 9M 2025.
• Rental expenses paid to Cpresso, LLC were $113,250 for Q3 2025 and $339,750 for 9M 2025.

Stakeholder Impact

• Shareholders: The significant Q3 net loss, revenue decline, and substantial decrease in cash and cash equivalents could negatively impact share price and investor confidence. Potential future equity financing poses a risk of dilution.
• Employees: Increased R&D personnel and sales force expansion suggest job growth in these areas, but the overall financial performance and cash burn could create uncertainty regarding long-term stability.
• Customers: New regulations on product packaging have already caused slower order placements, indicating potential disruptions or changes in product availability and offerings. Product mix adjustments are being made to meet evolving preferences.
• Suppliers: The concentration of suppliers (three major suppliers) could pose supply chain risks. Substantial amounts due to related party Shenzhen Feellife highlight significant reliance on this entity.
• Creditors: The decreased cash position and increased net cash used in operating activities could raise concerns about short-term liquidity, although management states existing resources are sufficient for the next twelve months.

Next Steps

• Expand sales force and grow market presence, which is expected to lead to increased selling and marketing expenses.
• Complete the initial public offering (IPO), which is expected to incur additional legal, accounting, corporate governance, and investor relations expenses.
• Recognize the remaining $3.6 million balance of contract liabilities as revenue within the next three months.
• Expand business operations, potentially necessitating additional equity financing to scale production capacity and address market demand.
• Fund future capital expenditures using existing cash balances, proceeds from bank loans, and proceeds from the IPO.
• Continue research and development activities, particularly for the new iPrefer series of E-vapors.

Key Dates

Recommendation

The Q3 2025 results show a concerning deterioration in performance, with a substantial net loss and a significant revenue decline attributed to regulatory changes. While nine-month revenues grew, the accompanying decrease in net income and gross profit margin, coupled with a dramatic reduction in cash and increased cash burn from operations, points to underlying operational inefficiencies and significant liquidity challenges. The company's reliance on future IPO proceeds and potential equity financing for growth, against a backdrop of increasing operating expenses and regulatory risks in the E-vapors market, suggests a high-risk investment profile with negative short-term momentum. A seasoned investor would likely view these trends as a strong signal to exit or avoid the stock until a clear path to profitability and improved cash flow is demonstrated.

Keywords

Hemp cannabinoid E-vapors, Consuming E-vapors, Medical nebulizers, SEC 10-Q, Quarterly Report, Financial results, Operating loss, Revenue decline, Gross profit margin, Related party transactions, Regulatory risk, E-cigarette industry, Vaping products, PAPA Medical Inc.